Abstract
Background: Long intergenic non-protein coding RNA 1116 (LINC01116)
plays a carcinogenic role in a variety of cancers. The study aims to investigate the roles
of LINC01116 and hsa-miR-9-5p (miR-9-5p) and fathom their interaction in chordoma.
Methods: The predicted binding sites between miR-9-5p with LINC01116 and
phosphoglycerate kinase 1 (PGK1) by starBase were confirmed through dual-luciferase
reporter assay. The behaviors of chordoma cells undergoing transfection with
siLINC01116 or miR-9-5p inhibitor were determined by Cell Counting Kit-8 (CCK-8),
colony formation, Transwell, and flow cytometry assays. The glucose consumption,
lactate production, and adenosine triphosphate (ATP) production of chordoma cells were
examined with specific kits. Quantitative real-time polymerase chain reaction (qRT-PCR)
and Western blot were performed to determine relevant gene expressions in chordoma
cells.
Results: Silencing of LINC01116 facilitated the apoptosis and expressions of Bcl-2-
associated X (Bax), cleaved caspase-3 (C caspase-3) and miR-9-5p while repressing
the cell cycle, viability, proliferation, invasion, glucose consumption, lactate production,
ATP production, and expressions of PGK1 and Bcl-2. Meanwhile, LINC01116 sponged
miR-9-5p, which could target PGK1. Moreover, the miR-9-5p inhibitor acted contrarily
and reversed the role of siLINC01116 in chordoma cells. Besides, LINC01116
downregulation facilitated apoptosis and attenuated the proliferation and invasion of
chordoma cells as well as PGK1 expression by upregulating miR-9-5p expression.
Conclusion: LINC01116/miR-9-5p plays a regulatory role in the progression of
chordoma cells and is a potential biomarker for chordoma.
[1]
Harsh GR IV, Vaz-Guimaraes F. Chordomas and chondrosarcomas of the skull base and spine. Massachusetts: Academic Press 2017.
[15]
Hu H, Chen Q, Ding SJERMPS. LncRNA LINC01116 competes with miR-145 for the regulation of ESR1 expression in breast cancer. Eur Rev Med Pharmacol Sci 2018; 22(7): 1987-93.
[16]
Su X, Zhang J, Luo X, Yang W, Liu Y, Liu Y, et al. LncRNA LINC01116 promotes cancer cell proliferation, migration and invasion in gastric cancer by positively interacting with lncRNA CASC11. OncoTargets Ther 2019; 12(7): 8117-23.
[17]
Fang Y, Huang Z, Li H, Tan W, Zhang Q, Wang L, et al. LINC01116 promotes the progression of epithelial ovarian cancer via regulating cell apoptosis. Eur Rev Med Pharmacol Sci 2018; 22(16): 5127-33.
[34]
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 2018; 9: 409.
[41]
Meng L, Xing Z, Guo Z, Liu ZJCD. LINC01106 post-transcriptionally regulates ELK3 and HOXD8 to promote bladder cancer progression. Cell Death & Dis 2020; 11(12): 1-15.
[42]
Zeng L, Lyu X, Yuan J, Wang W, Zhao N, Liu B, et al. Long non-coding RNA LINC01116 is overexpressed in lung adenocarcinoma and promotes tumor proliferation and metastasis. Am J Transl Res 2020; 12(8): 4302-13.
[43]
Zhang Z, Xu H, Hu W, Hu T, Wang XJERMPS. LINC01116 promotes proliferation, invasion and migration of osteosarcoma cells by silencing p53 and EZH2. Eur Rev Med Pharmacol Sci 2019; 23(16): 6813-23.
[46]
Fan X, Sun Y, Guo X, He C, Han B, Sun XJCB. Long non-coding RNA LINC01116 regulated miR-744-5p/SCN1B axis to exacerbate lung squamous cell carcinoma. Cancer Biomark 2020; 28(4): 1-10.
[57]
Chen Z, Tao Q, Qiao B. Silencing of LINC01116 suppresses the development of oral squamous cell carcinoma by up-regulating microRNA-136 to inhibit FN1. Cancer Manag Res 2019; 11: 6043-59.
[58]
Yuan W, Sun H, Yu LJB. Long non-coding RNA LINC01116 accelerates the progression of keloid formation by regulating miR-203/SMAD5 axis. Burns 2021; 47(3): 665-1675.